Andere talen Alkermes plc

Aandelen

ALKS

IE00B56GVS15

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 05-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
24,19 ^USD	+2,28%		+3,86%	-12,80%

24/05	ALKERMES PLC : Cantor Fitzgerald ontvangt een koopadvies	ZM
02/05	ALKERMES PLC : UBS handhaaft het verkoopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Alkermes to Participate in Two Upcoming Investor Conferences	29/05
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024	28/05
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk	02/05
Alkermes : Q1 2024 Earnings Call Script FINAL 5 1 2024	02/05
Alkermes : ALKS Q1 2024 Earnings Slides FINAL 5 1 2024	02/05
Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	01/05
Alkermes: Q1 Earnings Snapshot	01/05
Earnings Flash (ALKS) ALKERMES Reports Q1 Revenue $350.4M, vs. Street Est of $360.3M	01/05
Earnings Flash (ALKS) ALKERMES Posts Q1 EPS $0.43, vs. Street Est of $0.58	01/05
Alkermes plc Reiterates Earnings Guidance for the Year 2024	01/05
Alkermes plc Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
Alkermes plc Reports First Quarter 2024 Financial Results	01/05
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1	24/04
Alkermes to Report First Quarter Financial Results on May 1, 2024	17/04
Alkermes Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	10/04
BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024	09/04
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	09/04
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	09/04
Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	09/04
Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing	19/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Alkermes plc

Aandelen

ALKS

IE00B56GVS15

Andere talen

Filters